A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4484-4490

  Chu, Quincy S C ^a,e   Cianfrocca, Mary E ^b   Goldstein, Lori J ^b   Gale, Meg ^c   Murray, Nicholas ^c   Loftiss, Jill ^d   Arya, Nikita ^d   Koch, Kevin M ^d   Pandite, Lini ^d   Fleming, Ronald A ^d   Paul, Elaine ^d   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LAPATINIB; LETROZOLE; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; NITRILE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE; BREAST TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OVARY TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NITRILES; OVARIAN NEOPLASMS; QUINAZOLINES; TRIAZOLES;

EID: 51549101729     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4417     Document Type: Article

References (50)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
2. Slamon DJ, Clark GM, Wong GM, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Rubin Grandis JR, Melhem MR Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
4. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29: 27-36.
5. Rusch V, Baselga J, Cordon-Gardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53: 2379-85.
6. Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR, Harris AL. Presence of epidermal growth factor receptors as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985;38:1225-8.
7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
8. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
9. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61: 203-12.
10. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
11. Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer 2001;37: S16-22.
12. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. A p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
13. Bier H, Hoffman T, Hauser U, et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 2001;47:519-24.
14. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29:47-50.
15. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48.
16. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 inhibits HER-2 driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
17. Cobleigh MA, Vogel CL. Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
18. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
19. Vanhoefer U. Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22: 175-84.
20. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol ASCO Annu Meet Proc 2004;22:3006.
21. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94.
22. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-9.
23. Gomez HL, Chavez MA, Doval, et al. Results from a Phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer [abstract 1090]. Br Cancer Res Treat 2006;100:S68.
24. Baselga J, Carbonell X, Castaneda-Soda NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71.
25. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
26. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
27. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osbourne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-6s.
28. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3803-16.
29. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
30. Thurlimann B, Keshaviah A, Coates AS, et al.; Breast International Group (BIG) I-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
31. Hegde PS, Rusnak D, Bertiaux M, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007;6:1629-40.
32. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB- 2 inhibitor lapatinib. Oncologist 2004;9:10-5.
33. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13.
34. Hsieh S, Tobien T, Koch K. Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectroscopy system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 2004;18:285-92.
35. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events; 2003. DCTD, NCI, NIH, DHHS.
36. Chavey WE, Baum CS, Bleske BE, Harrison RV, Kesterson S, Nicklas JM. Guideline for the management of heart failure caused by systolic dysfunction. Part I. Guideline development, etiology, and diagnosis. Am Fam Physician 2001;64:769-74.
37. Therasse P, Arbuch SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
38. Munzone E, Curigliano G, Rocca A, et al. Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 2006;8:R4.
39. Johnston SR. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006;12:1061-8s.
40. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 2005;15: 889-99s.
41. Nicholson Rl, McClelland RA, Robertson JRF, Gee JMW. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373-87.
42. Shou J, Massarweh S, Osbourne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
43. Gee JM, Harper ME, Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/lressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003;144:5105-17.
44. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or secondline biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102: 43-9.
45. Chow LWC, Sun Y, Jassem J Phase 3 study of tem sirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract 6091] Breast Cancer Res Treat 2006;100:S286.
46. Polychronis A, Sinnett HD, Hadjiminas D, et al Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebocontrolled phase II randomized trial. Lancet Oncol 2005;6:383-91.
47. Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 2004;64:1213-30
48. Perez EA, Byrne JA. Results of an analysis of cardiac function in 3127 patients treated with lapatinib [abstract 583]. J Clin Oncol ASCO Annu Meet Proc 2006;23S.
49. Femara. Femara (letrozole) prescribing information; 2006. Product Monogram, Novartis.
50. Tykerb. Tykerb (lapatinib) prescribing information, 2007. Product Monogram, GlaxoSmith Kline.